Clinical trial · Observational
Perioperative Glutamine Supplementation and Cachexia
Perioperative Glutamine Supplementation Restores Atrophy of Psoas Muscle in Gastric Adenocarcinoma Patients Undergoing Gastrectomy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background Sarcopenia is characterized by the degenerative loss of skeletal muscle and is associated with increased adverse surgical outcomes. Glutamine is considered as an immune-modulating formula, which may stimulate protein synthesis in the skeletal muscle but also inhibited protein-degradation. In this study, the investigators calculate the area and volume psoas major muscle (PMMA; PMMV) of the third lumbar vertebral body as the reference of skeletal muscle. The aim of this study is to investigate whether perioperative glutamine supplementation restores atrophy of psoas muscle.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cachexia | — | UNRESOLVED | — |
| Glutamine; Metabolic Disorder | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SYMPT-X Glutamine, Oral Powder for Reconstitution | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- With glutamine supplementation
- description
- perioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
- interventionNames
- Drug: SYMPT-X Glutamine, Oral Powder for Reconstitution
- label
- Without glutamine supplementation
- description
- no glutamine use
- interventionNames
- Drug: SYMPT-X Glutamine, Oral Powder for Reconstitution
Primary outcomes (2)
- measure
- area psoas major muscle (PMMA; cm2)
- timeFrame
- 3 month after surgery
- description
- We hypothesized that glutamine might play a role in improving sarcopenia. Both the PMMA and total volume of the psoas major muscle (PMMV) represent the severity of sarcopenia, because CT is routinely performed in surgical GA patients to check for cancer recurrence. The reason of including total volume into analysis is that it is considered a better index to define sarcopenia. \[21\] The primary and secondary endpoints were the perioperative change of PMMA and PMMV, respectively.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * gastric cancer patients undergoing gastrectomy Exclusion Criteria: * hepatic or renal failures
References
Publications (0)
Data not yet available